β-adrenoceptor agonist effects in experimental models of bladder dysfunction.

Area of Science:

• Pharmacology
• Urology
• Physiology

Background:

• Beta-adrenoceptor stimulation influences urinary bladder storage.
• The beta-3 adrenoceptor subtype is likely the primary mediator in humans.
• Bladder storage dysfunction affects a significant population.

Purpose of the Study:

• To evaluate the efficacy of beta-adrenoceptor agonists in improving bladder storage function.
• To investigate the role of beta-3 adrenoceptors in various bladder dysfunction models.
• To assess the potential of beta-3 adrenoceptor agonists as therapeutic agents.

Main Methods:

• In vitro and in vivo studies using healthy animals and animal models of bladder dysfunction.
• Models included chemical irritation, obstruction, stroke, diabetes, and genetic hypertension.
• Evaluation of beta-adrenoceptor agonist effects on bladder storage parameters.

Main Results:

• Beta-adrenoceptor agonists consistently improved bladder storage function across diverse animal models.
• Effects were observed in models of irritation, obstruction, neurological disorders, and metabolic conditions.
• Agonist efficacy was generally unaffected by common beta-3 adrenoceptor gene polymorphisms.

Conclusions:

• Beta-adrenoceptor agonists demonstrate significant potential for treating bladder storage dysfunction.
• The findings support the development of beta-3 adrenoceptor agonists as a therapeutic strategy.
• Clinical studies, such as those for mirabegron, provide further support for this approach.